drug costs

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drug-makers are fighting the negotiations with lawsuits.

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

A new report by AARP found that the top 25 drugs — covered under Medicare Part D — have almost tripled in price since they first entered the market.

The state alleges the federal agency violated the Freedom of Information Act. The revised lawsuit includes allegations that the FDA did not properly respond to a records request submitted in May.

Medicare soon will start something it hasn't done in its 58-year history: negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.

To drive down costs, insurers are delivering high-priced infusion drugs via third-party pharmacies. Hospitals and clinics are trying to convince states to limit this practice, known as "white bagging."

Under the proposal, the Centers for Medicare and Medicaid Services would require as many as 10 drug-makers every year to furnish information to support the price it charges states, which administer Medicaid.

Drug-makers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Florida has already taken action. Now, Congress is finally on board, too, but will it matter?

The state has filed another lawsuit alleging that the FDA violated the Freedom of Information Act by not properly responding to a request for records about Florida’s attempt to get approval for its proposal.